Brainomix, a UK-based imaging diagnostics software spinout from University of Oxford, secured £7m ($9.8m) on Tuesday from backers including Oxford University Innovation (OUI) Fund,  owned by the university’s tech transfer office, OUI.

The round was led by Parkwalk Advisors, a fund management arm of commercialisation firm IP Group. Chimera Partners and Boehringer Ingelheim Venture Fund, a corporate venturing vehicle of pharmaceutical developer Boehringer Ingelheim, also took part.

Founded in 2010, Brainomix has designed artificial intelligence-powered diagnostics software that helps flag up…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?